FY2030 Earnings Forecast for Valneva Issued By HC Wainwright

Valneva SE Sponsored ADR (NASDAQ:VALN) – Equities research analysts at HC Wainwright lowered their FY2030 EPS estimates for shares of Valneva in a report issued on Thursday, March 19th. HC Wainwright analyst B. Folkes now expects that the company will post earnings per share of $3.78 for the year, down from their prior forecast of $3.84. The consensus estimate for Valneva’s current full-year earnings is $0.13 per share.

Separately, Wall Street Zen lowered Valneva from a “hold” rating to a “sell” rating in a research note on Saturday, December 6th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Valneva presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.

Valneva Stock Performance

Shares of VALN opened at $10.32 on Friday. Valneva has a 1 year low of $5.43 and a 1 year high of $12.25. The company’s 50 day simple moving average is $10.29 and its 200 day simple moving average is $9.68. The company has a market capitalization of $888.66 million, a price-to-earnings ratio of -6.53 and a beta of 1.80. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.36 and a current ratio of 2.38.

Institutional Trading of Valneva

A number of hedge funds and other institutional investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. bought a new stake in shares of Valneva in the fourth quarter worth $44,000. VSM Wealth Advisory LLC boosted its stake in Valneva by 125.0% during the 3rd quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock valued at $110,000 after acquiring an additional 5,000 shares during the last quarter. JPMorgan Chase & Co. acquired a new position in Valneva during the 3rd quarter worth $124,000. XTX Topco Ltd acquired a new position in Valneva during the 4th quarter worth $94,000. Finally, Marex Group plc acquired a new position in Valneva during the 2nd quarter worth $64,000. 11.39% of the stock is owned by hedge funds and other institutional investors.

Valneva Company Profile

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.